Europe — EMA
Onkotrone (Mitoxantrone)
Mitoxantrone, the active ingredient in Onkotrone, is an antineoplastic presented as a unknown/unknown for intrapleural; intravenous use. It treats certain hematologic malignancies and solid tumours in adult patients.
Request sourcing
What is Mitoxantrone?
Mitoxantrone, the active ingredient in Onkotrone, is an antineoplastic presented as a unknown/unknown for intrapleural; intravenous use. It treats certain hematologic malignancies and solid tumours in adult patients. GNH USA supplies Onkotrone as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.
GNH USA supplies Onkotrone as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.
What is Mitoxantrone used for?
Mitoxantrone is used in oncology for cancers that involve DNA replication pathways.
- Acute lymphoblastic leukaemia (ALL): Improves the remission rate in patients under intensive chemotherapy. - Acute myeloid leukaemia (AML) : Provides a treatment option for patients with refractory disease or relapse after standard therapy. - Breast distant metastasis : Used in combination with the drug of the ‑ ‑ --- --- ... .... .... .... ... … .... … … … … … … ... …
